Table 1.

The clinicopathologic characteristics of patients in the training and validation cohorts

Clinical and pathologicTraining cohortValidation cohort
IndexesN = 133%N = 123%P
Age (y)
 ≤506145.866452.030.324
 >507254.145947.97
Sex
 Female2115.7986.50.019
 Male11284.2111593.5
Liver cirrhosis
 No2317.292923.580.212a
 Yes11082.719476.42
Child–Pugh
 A13299.2512299.191.000
 B10.7510.81
HBsAg
 Negative2418.05129.760.057
 Positive10981.9511190.24
ALT (U/L)
 ≤406951.887560.980.143
 >406448.124839.02
AFP (ng/mL)
 ≤205944.363730.080.164
 >207455.648669.92
Tumor encapsulation
 Complete7354.897762.60.211
 None6045.114637.4
Tumor differentiation
 I–II9672.188367.480.413
 III–IV3727.824032.52
Tumor size (cm)
 ≤59873.688065.040.133
 >53526.324334.96
Tumor number
 Single12090.2311291.060.820
 Multiple139.77118.94
Vascular invasion
 No8664.667863.410.835
 Yes4735.344536.59
BCLC
 0+A8261.6510182.11<0.001
 B+C5138.352217.89

Abbreviation: HBsAg, hepatitis B surface antigen.

  • aFisher exact test.